Login
Companies $RXST
$5.29 -$0.01 (0.19%) After hours
RxSight, Inc. logo

RxSight, Inc.

rxsight.com

What Do They Do?

Sells adjustable lenses and light-delivery devices that let eye surgeons customize patients’ vision after cataract surgery, to surgery centers, hospitals and physician practices.

Who Are Their Customers?

RxSight sells to surgery centers, hospitals and physician practices through its U.S. direct sales and account teams; international customers include distributors.

Do Revenues Turn Into Profits?

No. It lost $38.9M in FY2025.

Operating income, FY2025
−36% of revenue
▼ −31% (Loss) vs FY2024 (−$36.9M, −26%)
Net income, FY2025
−29% of revenue
▼ −42% (Loss) vs FY2024 (−$27.5M, −20%)
Free cash flow, FY2025
−14% of revenue
▲ +14% (Loss) vs FY2024 (−$22.4M, −16%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −19%
vs $30.3M in Q3 FY2025
Net income
▼ −65% (Loss)
vs −$9.8M in Q3 FY2025
  • Aug 5, 2026 RxSight withdrew its 2026 financial guidance It said formal guidance would resume in early 2027.
  • Jul 15, 2026 Aziz Mottiwala was appointed CEO, replacing Ron Kurtz Kurtz will transition to chief medical officer.
  • Jul 6, 2026 RxSight signed an Alcon deal to develop adjustable cataract lenses Alcon will commercialize the products; RxSight will develop and manufacture them and receive upfront, milestone and royalty payments.
Revenue over time
L D D LAL Service Warranty, Service Contracts, And Accessories
$200M$100M$0

Who Do They Compete With?

Competes with Alcon and Johnson & Johnson

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support